Novartis Phase 3 Trial for Hemoglobinuria Drug Iptacopan Met Primary Endpoint
08 Dezembro 2022 - 4:12AM
Dow Jones News
By Pierre Bertrand
Novartis AG said Thursday that a Phase 3 trial for its drug
iptacopan has met its primary endpoint of boosting hemoglobin
levels.
The Swiss pharma company said the trial showed that patients
treated twice daily with the drug achieved clinically meaningful
hemoglobin-level increases without the need for blood transfusions
at 24 weeks.
Iptacopan is a treatment for blood disease paroxysmal nocturnal
hemoglobinuria, which causes the premature death of red blood
cells. Patients with PNH suffer anemia, fatigue and require blood
transfusions.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
December 08, 2022 01:57 ET (06:57 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024